Methox-F

Methotrexate, the active ingredient in Methox-F, is an antimetabolite presented as a subcutaneous injection for subcutaneous use. It is approved in the European Union for adult patients with rheumatoid arthritis, psoriasis, acute lymphoblastic leukemia and non‑Hodgkin lymphoma, where it helps control disease activity and limit abnormal cell growth.

GNH USA supplies Methox-F as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Methotrexate is used across several autoimmune and oncologic disease pathways. - Rheumatoid arthritis: reduces joint inflammation and slows structural damage. - Psoriasis: diminishes skin plaque formation and severity. - Acute lymphoblastic leukemia: interferes with malignant lymphoblast proliferation. - Non‑Hodgkin lymphoma: impedes growth of malignant lymphoid cells.

Methotrexate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset occurring shortly after administration. - Fatigue: persistent tiredness not relieved by rest. - Oral mucositis: painful sores or ulceration of the mouth lining. - Cytopenias: reduced white blood cells, red blood cells, or platelets. - Elevated liver enzymes: indication of hepatic stress. - Alopecia: temporary hair thinning or loss.

Serious or Rare Side Effects: - Severe hepatotoxicity: potential liver fibrosis or cirrhosis. - Pulmonary toxicity: interstitial pneumonitis or fibrosis. - Life‑threatening infections: due to profound immunosuppression. - Bone marrow aplasia: marked suppression of blood cell production. - Renal failure: impaired kidney function, especially with high doses. - Secondary malignancies: rare emergence of new cancers.

Methox-F requires careful monitoring to minimize risks. - Liver function monitoring: perform baseline and periodic liver enzyme tests. - Hematologic surveillance: regularly check complete blood counts. - Renal function assessment: evaluate serum creatinine and clearance before and during therapy. - Pregnancy avoidance: contraindicated in pregnancy; ensure effective contraception. - Concomitant drug review: avoid use with known hepatotoxic or nephrotoxic agents. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methotrexate can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase methotrexate toxicity. - Penicillins and sulfonamides: may enhance hematologic suppression. - Live vaccines: risk of severe infection due to immunosuppression. - Alcohol: potentiates hepatic injury. - High‑dose folate antagonists: exacerbate cytotoxic effects.

Moderate Interactions (Monitor Closely): - Proton pump inhibitors: may affect renal clearance. - Diuretics (especially thiazides): increase serum methotrexate levels. - Azathioprine: additive bone‑marrow suppression. - Warfarin: potential for altered anticoagulation. - Trimethoprim: may raise methotrexate concentrations.